» Articles » PMID: 17721626

Prothrombotic Markers and Early Spontaneous Recanalization in ST-segment Elevation Myocardial Infarction

Overview
Journal Thromb Haemost
Publisher Thieme
Date 2007 Aug 28
PMID 17721626
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We tested the hypothesis that selected prothrombotic biomarkers might be associated with early spontaneous coronary recanalization in patients with ST-segment elevation acute myocardial infarction (STEMI). We prospectively enrolled 123 patients with STEMI including 53 patients with spontaneous coronary recanalization (cases) and 70 patients with persistent occlusion (controls) at the time of emergent coronary angiography and before angioplasty. All had received aspirin and heparin. Blood samples were collected immediately before angioplasty to measure soluble P-selectin, circulating microparticles originating from platelets (PMPs), granulocytes (GMPs), endothelial cells (EMPs); tissue factor-associated MP (TF-MP); soluble platelet glycoprotein V (sGPV) and prothrombin F1 + 2; tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and plasmin-antiplasmin (PAP). A sub-group of 70 patients (35 cases, 35 controls) was available for flow cytometry analysis of platelet P-selectin and activated GPIIb-IIIa. Baseline clinical characteristics did not differ between groups except for more frequent hypertension and dyslipidemia in controls. Platelet activation markers and PMP did not differ between the two groups. Controls had higher numbers of EMPs and GMPs compared to cases, but the difference was no longer significant when corrected for risk factors. Controls differed from cases by higher plasma levels of sGPV [64 (47-84) ng/ml vs. 53 (44-63) ng/ml] and PAP [114(65-225) ng/ml vs. 88 (51-147) ng/ml]. The difference persisted after adjustment for risks factors (p = 0.031 and 0.037, respectively). Persistent occlusion of the infarct related artery is associated with some markers related to higher thrombin (sGPV) and plasmin (PAP) production but is not associated with markers of platelet activation.

Citing Articles

Angiopoietin-like protein 2 inhibits thrombus formation.

Zhang T, Zhang M, Guo L, Liu D, Zhang K, Bi C Mol Cell Biochem. 2024; 480(2):1169-1181.

PMID: 38880861 PMC: 11835982. DOI: 10.1007/s11010-024-05034-9.


Diagnostic Impact of Radiological Findings and Extracellular Vesicles: Are We Close to Radiovesicolomics?.

Serafini F, Lanuti P, Delli Pizzi A, Procaccini L, Villani M, Taraschi A Biology (Basel). 2021; 10(12).

PMID: 34943180 PMC: 8698452. DOI: 10.3390/biology10121265.


Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease.

Baidildinova G, Nagy M, Jurk K, Wild P, Ten Cate H, van der Meijden P Front Cardiovasc Med. 2021; 8:684920.

PMID: 34235190 PMC: 8255615. DOI: 10.3389/fcvm.2021.684920.


Biology and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis.

Zara M, Guidetti G, Camera M, Canobbio I, Amadio P, Torti M Int J Mol Sci. 2019; 20(11).

PMID: 31212641 PMC: 6600675. DOI: 10.3390/ijms20112840.


The Release of Monocyte-Derived Tissue Factor-Positive Microparticles Contributes to a Hypercoagulable State in Idiopathic Membranous Nephropathy.

Wang G, Lu J, Ma K, Zhang Y, Hu Z, Chen P J Atheroscler Thromb. 2018; 26(6):538-546.

PMID: 30429407 PMC: 6545459. DOI: 10.5551/jat.46284.


References
1.
Yusuf S, Mehta S, Chrolavicius S, Afzal R, Pogue J, Granger C . Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295(13):1519-30. DOI: 10.1001/jama.295.13.joc60038. View

2.
Aleil B, Meyer N, Wolff V, Kientz D, Wiesel M, Gachet C . Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost. 2006; 96(4):505-11. View

3.
Schwertz H, Tolley N, Foulks J, Denis M, Risenmay B, Buerke M . Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med. 2006; 203(11):2433-40. PMC: 2118136. DOI: 10.1084/jem.20061302. View

4.
Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F . Procoagulant microparticles: disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol. 2006; 26(12):2594-604. DOI: 10.1161/01.ATV.0000246775.14471.26. View

5.
Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet J . Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 2006; 26(12):2775-80. DOI: 10.1161/01.ATV.0000249639.36915.04. View